Ocugen said the Food and Drug Administration lifted a clinical hold on its OCU200 investigational treatment for diabetic macular edema, paving the way for Phase 1 trials.
DME is one of the most common vision-threatening diseases occurring in people with diabetes and includes blurriness in vision and progressive vision loss as the disease progresses. Approximately ...